In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
The Overview: July 2026
SummeRun Raises $260,000+ for Research, Hope and Progress Nearly one thousand runners, walkers, survivors, families, friends, and supporters showed up at Seattle’s Seward Park on Sunday, July 12th, for the 33rd annual Ovarian Cancer Research Alliance (OCRA) Rivkin Family SummeRun, raising more than $260,000 for research and programs that support the gynecologic cancer community. The … Continued
OCRA’s Advocate’s Corner: July 2026
Written by Julia Thayer, OCRA’s Associate Director, Advocacy Federal Rulemaking Update: Proposed Update to Uniform Guidance Advocacy isn’t limited to legislation and federal funding. This month, OCRA submitted a public comment on a proposed federal rule that could significantly impact how biomedical research is funded and conducted. On May 29, 2026, the Office of Management … Continued
Navigating Platinum-Resistant Ovarian Cancer: Everyday Health Shares Coping Strategies and OCRA Resources
In an article published by Everyday Health, “Coping With the Emotional Challenges of Platinum-Resistant Ovarian Cancer” (June 10, 2026), Ovarian Cancer Research Alliance (OCRA) community member Amanda Widro shares her experience navigating a platinum-resistant ovarian cancer diagnosis. Ovarian cancer is considered platinum-resistant when it recurs within six months of finishing platinum-based chemotherapy. Widro, who was … Continued